Insulin and C-peptide responses to glucose load in cystic fibrosis. 1985

V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan

Immunoreactive Insulin and C-peptide responses to glucose load were estimated in patients with cystic fibrosis and in controls. Both insulin and C-peptide responses were low in cystic fibrosis patients and the changes were more marked in those with glucose intolerance. There appears to be true pancreatic hyposecretion of insulin in patients with cystic fibrosis whereas the peripheral sensitivity of insulin seems to be normal or enhanced.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral

Related Publications

V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
January 1988, Diabete & metabolisme,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
June 1986, Diabete & metabolisme,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
April 1988, Diabetes research (Edinburgh, Scotland),
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
December 1991, Diabetes,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
January 1982, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
January 1987, Acta physiologica Polonica,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
November 1982, Zhonghua yi xue za zhi,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
June 1984, Journal of the Egyptian Society of Parasitology,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
January 1985, Diabetes care,
V Mohan, and V Alagappan, and C Snehalatha, and A Ramachandran, and K V Thiruvengadam, and M Viswanathan
September 1980, Diabetologia,
Copied contents to your clipboard!